These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26865352)

  • 1. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.
    Ben Ami E; Demetri GD
    Expert Opin Drug Saf; 2016; 15(4):571-8. PubMed ID: 26865352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
    Jang BH; Kim BW; Lim KJ; Kim BG; Park SM; Kim JS; Ji JS; Choi H
    Korean J Gastroenterol; 2015 Jun; 65(6):366-9. PubMed ID: 26087692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors.
    Farag S; Verschoor AJ; Bosma JW; Gelderblom H; Kerst JM; Sleijfer S; Steeghs N
    J Clin Pharmacol; 2015 Aug; 55(8):920-5. PubMed ID: 25810235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A successful approach to overcome imatinib-induced skin toxicity in a GIST patient.
    Desar IM; van Herpen CM; van Erp NP; Kaal SE; van de Kerkhof PC; van der Graaf WT
    Anticancer Drugs; 2016 Jul; 27(6):576-9. PubMed ID: 26982239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor.
    Luo JR; Xiang XJ; Xiong JP
    Int J Clin Pharmacol Ther; 2016 Sep; 54(9):719-22. PubMed ID: 27345285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
    Rehman H; Hakim N; Sugarman R; Seetharamu N; Saif MW
    J Oncol Pharm Pract; 2020 Sep; 26(6):1511-1515. PubMed ID: 32067560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?
    Hompland I; Bruland ØS
    Anticancer Res; 2015 Nov; 35(11):5759-65. PubMed ID: 26503996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].
    Raccah E; Merimsky O; Kuten A; Apter S; Catane R
    Harefuah; 2007 May; 146(5):329-34, 408. PubMed ID: 17674545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
    Gold JS; Dematteo RP
    Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Story of Imatinib in GIST - a Journey through the Development of a Targeted Therapy.
    Reichardt P
    Oncol Res Treat; 2018; 41(7-8):472-477. PubMed ID: 29895025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
    Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
    Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Drug and Possible New Toxicity - Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors.
    Inayat F; Saif MW
    Anticancer Res; 2016 Nov; 36(11):6201-6204. PubMed ID: 27793952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.
    Maki RG; Blay JY; Demetri GD; Fletcher JA; Joensuu H; Martín-Broto J; Nishida T; Reichardt P; Schöffski P; Trent JC
    Oncologist; 2015 Jul; 20(7):823-30. PubMed ID: 26070915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety profile of imatinib in CML and GIST: long-term considerations.
    Thanopoulou E; Judson I
    Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
    Griffin JM; Amand MS; Demetri GD
    Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
    Ishikawa T; Kanda T; Kosugi S; Yajima K; Hatakeyama K
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):916-21. PubMed ID: 21677482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
    Schindler CG; Armbrust T; Gunawan B; Langer C; Füzesi L; Ramadori G
    Z Gastroenterol; 2005 Mar; 43(3):267-73. PubMed ID: 15765299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.